Literature DB >> 7678418

Mitogen-activated protein kinase stimulation by a tyrosine kinase-negative epidermal growth factor receptor.

E Selva1, D L Raden, R J Davis.   

Abstract

Mutation of the epidermal growth factor receptor (EGF-R) within the ATP binding subdomain results in a receptor that lacks tyrosine kinase activity and is defective in signal transduction. However, this kinase-negative EGF-R is able to activate MAP kinase (Campos-Gonzalez, R., and Glenny, J. R. (1992) J. Biol. Chem. 267, 14535-14538). This observation suggests that signal initiation by the EGF-R can occur by a mechanism that is independent of the receptor tyrosine kinase activity. Here, we report that the kinase-negative EGF-R is phosphorylated on tyrosine in EGF-treated cells. The mechanism of tyrosine phosphorylation can be accounted for by the action of EGF to stimulate a protein kinase activity that is associated with the kinase-negative EGF-R. This protein kinase activity is not intrinsic to the receptor and can be separated from the EGF-R by incubation with 0.5 M NaCl. MAP kinase activation by the kinase-negative EGF-R may therefore occur by a mechanism that requires a receptor-associated tyrosine kinase. Thus, it is unnecessary to propose a novel kinase-independent mechanism of signal initiation to account for MAP kinase activation by the kinase-negative EGF-R.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678418

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Nucleotide-binding properties of kinase-deficient epidermal-growth-factor-receptor mutants.

Authors:  K Cheng; J G Koland
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

2.  Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins.

Authors:  M L Vignais; H B Sadowski; D Watling; N C Rogers; M Gilman
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

3.  Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein.

Authors:  S L Sierke; K Cheng; H H Kim; J G Koland
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

Review 4.  Autophosphorylation: a salient feature of protein kinases.

Authors:  J A Smith; S H Francis; J D Corbin
Journal:  Mol Cell Biochem       Date:  1993-11       Impact factor: 3.396

5.  Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction.

Authors:  G C Huang; X Ouyang; R J Epstein
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

6.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

Review 7.  Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment.

Authors:  R Radinsky
Journal:  Cancer Metastasis Rev       Date:  1995-12       Impact factor: 9.264

8.  A kinase-negative epidermal growth factor receptor that retains the capacity to stimulate DNA synthesis.

Authors:  K J Coker; J V Staros; C A Guyer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

9.  Activation of c-fos gene expression by a kinase-deficient epidermal growth factor receptor.

Authors:  E R Eldredge; G M Korf; T A Christensen; D C Connolly; M J Getz; N J Maihle
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

10.  Anisomycin-activated protein kinases p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are implicated in the induction of c-fos and c-jun.

Authors:  E Cano; C A Hazzalin; L C Mahadevan
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.